Beneficial electrophysiological effects of trimetazidine in patients with postischemic chronic heart failure.
The aim of the study was to assess whether trimetazidine (TMZ) could affect dispersion of atrial depolarization and ventricular repolarization. Corrected QT interval (QTc), QTc dispersion (QTc-d), Tpeak-Tend, and Tpeak-Tend dispersion (Tpeak-Tend-d) were measured in 30 patients with chronic heart failure (CHF) before and 6 months after randomization to conventional therapy plus TMZ (17 patients) or conventional therapy alone (13 patients). After 6 months, QTc was significantly reduced in both groups, whereas QT-peak was increased only in control group. Tpeak-Tend-d decreased (from 63.53 +/- 24.73 to 42.35 +/- 21.07 milliseconds, P = .006) only in TMZ group. When subgrouped according to CHF etiology, only ischemic patients on TMZ showed Tpeak-Tend-d reduction (65.00 +/- 27.14 vs 36.67 +/- 11.55 milliseconds, P = .001 in ischemic patients; 60.00 +/- 20.00 vs 56.00 +/- 33.86 milliseconds, P = NS, in nonischemic). These electrophysiological properties indicate an undiscovered mechanism of action of TMZ, which could be useful in conditions at risk of major arrhythmias.
Cera
Michela
M
Clinical Cardiology-Heart Failure Unit, San Raffaele Scientific Institute, Milan, Italy. michelacera@gmail.com
Salerno
Anna
A
Fragasso
Gabriele
G
Montanaro
Claudia
C
Gardini
Chiara
C
Marinosci
Giovanni
G
Arioli
Francesco
F
Spoladore
Roberto
R
Facchini
Alberto
A
Godino
Cosmo
C
Margonato
Alberto
A
D000368:Aged; D000369:Aged, 80 and over; D000987:Antisocial Personality Disorder / Q000453:epidemiology / Q000523:psychology; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy*; D002908:Chronic Disease; D004562:Electrocardiography / Q000187:drug effects; D022062:Electrophysiologic Techniques, Cardiac; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications; D012307:Risk Factors; D014292:Trimetazidine / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D014665:Vasodilator Agents; D014292:Trimetazidine